Squarepoint Ops LLC - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.

Quarter-by-quarter ownership
Squarepoint Ops LLC ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q2 2023$533,171
+105.6%
11,558
+106.5%
0.00%
+100.0%
Q4 2022$259,309
-95.0%
5,597
-95.6%
0.00%
-96.2%
Q3 2022$5,214,000
+67.7%
125,911
+141.6%
0.03%
+52.9%
Q2 2022$3,109,000
+40.0%
52,105
+70.4%
0.02%
+70.0%
Q1 2022$2,221,000
-65.2%
30,578
-54.4%
0.01%
-58.3%
Q2 2021$6,389,000
+1435.8%
67,005
+1735.8%
0.02%
+1100.0%
Q1 2021$416,000
-84.9%
3,650
-89.1%
0.00%
-94.6%
Q3 2020$2,756,000
+412.3%
33,537
+387.9%
0.04%
+311.1%
Q2 2020$538,000
-16.1%
6,874
-52.3%
0.01%
-43.8%
Q1 2020$641,000
-74.9%
14,417
-75.9%
0.02%
+6.7%
Q4 2019$2,550,000
+456.8%
59,716
+458.3%
0.02%
+275.0%
Q3 2019$458,000
-15.0%
10,696
+26.1%
0.00%
-20.0%
Q2 2019$539,000
-61.6%
8,485
-73.7%
0.01%
-68.8%
Q4 2018$1,402,000
+298.3%
32,253
+388.7%
0.02%
+128.6%
Q3 2017$352,000
+41.9%
6,600
+80.3%
0.01%0.0%
Q1 2017$248,000
+3.8%
3,660
+7.9%
0.01%
-30.0%
Q4 2016$239,000
-81.0%
3,393
-80.8%
0.01%
-88.0%
Q3 2016$1,256,000
+217.2%
17,700
+118.5%
0.08%
+232.0%
Q2 2016$396,000
+10.6%
8,100
+43.4%
0.02%
-10.7%
Q1 2016$358,000
+44.9%
5,648
+156.7%
0.03%
+3.7%
Q4 2015$247,0002,2000.03%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q3 2023
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 727,426$25,932,7374.72%
RTW INVESTMENTS, LP 5,405,089$192,691,4234.07%
First Light Asset Management, LLC 1,125,032$40,107,3913.81%
CHI Advisors LLC 215,000$7,664,7503.04%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 250,052$8,914,3543.00%
SPHERA FUNDS MANAGEMENT LTD. 259,135$9,238,1631.68%
Rock Springs Capital Management LP 1,476,441$52,635,1221.41%
SUVRETTA CAPITAL MANAGEMENT, LLC 679,459$24,222,7131.31%
Privium Fund Management B.V. 115,241$4,108,3411.22%
SECTOR GAMMA AS 115,166$4,105,6681.05%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders